• Ferritin-Based Hybrid Protein Particle Vaccine: Dual Antigen

  2026-04-30

  This study presents a novel ferritin-based hybrid protein particle vaccine that integrates both the influenza A M2e antigen and SARS-CoV-2 S-protein tandem epitopes. The approach leverages E. coli expression for efficient co-assembly, resulting in enhanced immunogenicity and promising cross-protective potential for next-generation combination vaccines.

• L-NMMA Acetate (SKU B6444): Reliable NOS Pathway Modulation

  2026-04-30

  This article explores how L-NMMA acetate (SKU B6444) empowers life science researchers to achieve reproducible, mechanistically rigorous studies of the nitric oxide pathway. Scenario-driven Q&A blocks address real experimental challenges in cell viability and differentiation assays, with actionable comparisons and protocol insights for biomedical labs.

• PYR-41, Inhibitor of Ubiquitin-Activating Enzyme E1: Applied

  2026-04-29

  PYR-41, a selective inhibitor of Ubiquitin-Activating Enzyme E1 from APExBIO, empowers researchers to dissect protein degradation, NF-κB pathway modulation, and inflammation with precision. Detailed workflow guidance, troubleshooting tips, and translational insights from the latest viral evasion research set this tool apart for advanced ubiquitination studies.

• Redefining VEGFR-3 Inhibition: SAR131675 in Fibrosis and Tum

  2026-04-29

  This thought-leadership article explores the strategic utility of SAR131675—a selective, ATP-competitive VEGFR-3 inhibitor—in advancing translational research on lymphangiogenesis, angiogenesis, tumor growth, and hepatic fibrosis. By integrating mechanistic insights with recent preclinical evidence, the article guides researchers in deploying SAR131675 for robust pathway interrogation, while critically evaluating its selectivity, experimental value, and translational limitations.

• G007-LK Tankyrase 1/2 Inhibitor: A Strategic Leap in APC-Mut

  2026-04-28

  Explore the mechanistic depth and translational strategy of G007-LK, a potent tankyrase 1/2 inhibitor, for Wnt/β-catenin pathway modulation in APC mutation colorectal cancer and beyond. This thought-leadership article integrates mechanistic insights, evidence-backed protocols, and strategic guidance for translational researchers, with a focus on workflow optimization and clinical relevance.

• X-press Tag Peptide: Precision N-terminal Leader for Protein

  2026-04-28

  X-press Tag Peptide streamlines affinity purification and detection in recombinant protein expression workflows, thanks to its unique N-terminal leader design and robust solubility profile. This guide translates recent mechanistic advances in neddylation research into actionable protocols, optimizing your use of APExBIO's high-purity tag peptide across challenging protein targets.

• Z-VDVAD-FMK: Precision Caspase-2 Inhibition for Apoptosis As

  2026-04-27

  Z-VDVAD-FMK delivers high specificity for caspase-2 inhibition, enabling refined apoptosis and mitochondrial pathway studies in diverse cellular models. Its robust solubility and workflow-validated protocols ensure reproducible results, from cancer research to advanced antiviral mechanistic studies.

• Low-Molecular Weight Inhibitors Targeting the Alternative Co

  2026-04-27

  This review highlights how low-molecular weight inhibitors, particularly those targeting complement factor B and D, are advancing the therapeutic modulation of the alternative complement pathway. The paper details the rationale, development, and early translational progress of these oral agents, emphasizing their potential in managing complement-mediated diseases such as PNH, aHUS, and C3 glomerulopathy.

• G007-LK Tankyrase 1/2 Inhibitor: Optimizing Wnt Pathway Rese

  2026-04-26

  G007-LK, a potent and selective tankyrase 1/2 inhibitor from APExBIO, enables high-precision modulation of Wnt/β-catenin and Hippo signaling in cancer research models. Applied correctly, it provides unique mechanistic insights and workflow advantages in APC mutation colorectal cancer and hepatocellular carcinoma assays.

• AP20187 as a Precision Switch: Enabling Conditional Gene The

  2026-04-25

  Explore how AP20187, a chemical inducer of dimerization, advances conditional gene therapy by enabling dynamic, pathway-specific control. This article uniquely bridges AP20187’s molecular mechanism with recent discoveries in autophagy and cancer signaling, guiding researchers toward more informed assay design.

• Metformin Hydrochloride: Mechanistic Insights & Translationa

  2026-04-24

  This thought-leadership article explores Metformin Hydrochloride (Metformin HCl) as a paradigm-shifting tool in translational metabolism and bone biology research. Focusing on its mechanistic effects—from AMPK signaling modulation and inhibition of hepatic gluconeogenesis to the suppression of pathological bone formation via the Nr4a1/Wnt/β-catenin axis—this piece offers actionable protocol guidance and strategic perspectives for researchers. The article highlights APExBIO's product as a reliable research standard and uniquely bridges metabolic and musculoskeletal applications, with evidence-labeled claims throughout.

• Spermine: Endogenous Polyamine for Potassium Channel Modulat

  2026-04-24

  Spermine stands apart as a high-purity, endogenous polyamine enabling precise modulation of inward rectifier potassium channels and nuclear envelope dynamics. This guide details experimental workflows, protocol optimizations, and troubleshooting strategies, empowering researchers to harness Spermine for advanced cellular metabolism and membrane fusion studies.

• Asunaprevir (BMS-650032): Optimizing HCV RNA Replication Inh

  2026-04-23

  Asunaprevir (BMS-650032) stands out as a potent, genotype-spanning HCV NS3 protease inhibitor with broad utility in virology research. This article delivers actionable experimental workflows, protocol enhancements, and troubleshooting tips to maximize reproducibility and data quality using Asunaprevir from APExBIO.

• XPO1 Inhibition Modulates Wnt/β-Catenin Signaling in CRC Mod

  2026-04-23

  This study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, suppresses colorectal cancer (CRC) tumorigenesis by modulating the Wnt/β-catenin signaling pathway and reducing COX-2 expression. The findings highlight XPO1 inhibition as a promising chemopreventive strategy in CRC, with implications for both preclinical modeling and translational research.

• Applied Workflows with Angiotensin I in Cardiovascular Resea

  2026-04-22

  Harnessing Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) enables precise modeling of the renin-angiotensin system for cardiovascular and neuroendocrine research. This guide unpacks advanced experimental workflows, cross-domain insights, and troubleshooting strategies that leverage APExBIO’s high-purity peptide for robust, reproducible data.

11234 records 1/749 page Next 12345 下5页 Last page